
June 2023 ACIP Meeting - Dengue Vaccines 2023 Access Resources LectureEN About In this ACIP meeting, experts reviewed dengue vaccination strategies using the Notre Dame and Takeda models. Dr. Wilbur Chen noted prior dengue infection doesn't fully protect against severe complications from different virus types; Dengvaxia was approved for children aged 9 to 16 in endemic areas. The workgroup evaluates TAK-003 from Takeda, considering policy and economic impacts, aiming for a recommendation by October 2023 pending licensure. Dr. Hernandez used the PICO framework for policy questions, emphasizing endemic area residents. Dr. Kaul presented economic models for Puerto Rico. Varied efficacy for Dengue 3 and 4 and the impact of pre-vaccination screening on cost-effectiveness were discussed, emphasizing age and serostatus in vaccination strategies. Tags Focus Area: Infectious Disease Audiences: Nurses; Physicians; Public Health Professionals Emergency Management Stage: Preparedness (Prevention / Protection) Keywords: Dengue; Dengue Virus; Mosquito-Borne Diseases; Dengue Vaccines; Mosquito Vectors Institutions: Centers for Disease Control and Prevention (CDC) More like this Surveillance for Emerging Threats to Pregnant Women and Infants: Data for Action 2018 · Centers for Disease Control and Prevention (CDC) Measles Outbreak: Vital Updates for Your Practice 2024 · Children's Hospital of Philadelphia, Centers for Disease Control and Prevention (CDC), Hofstra University, WebMD Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 2024 · Centers for Disease Control and Prevention (CDC), Maximus Federal Services, Inc., ICF The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Access Resources LectureEN

June 2023 ACIP Meeting - Dengue Vaccines

2023

Access Resources

LectureEN

About

In this ACIP meeting, experts reviewed dengue vaccination strategies using the Notre Dame and Takeda models. Dr. Wilbur Chen noted prior dengue infection doesn't fully protect against severe complications from different virus types; Dengvaxia was approved for children aged 9 to 16 in endemic areas. The workgroup evaluates TAK-003 from Takeda, considering policy and economic impacts, aiming for a recommendation by October 2023 pending licensure. Dr. Hernandez used the PICO framework for policy questions, emphasizing endemic area residents. Dr. Kaul presented economic models for Puerto Rico. Varied efficacy for Dengue 3 and 4 and the impact of pre-vaccination screening on cost-effectiveness were discussed, emphasizing age and serostatus in vaccination strategies.

More like this

Surveillance for Emerging Threats to Pregnant Women and Infants: Data for Action 2018 · Centers for Disease Control and Prevention (CDC) Measles Outbreak: Vital Updates for Your Practice 2024 · Children's Hospital of Philadelphia, Centers for Disease Control and Prevention (CDC), Hofstra University, WebMD Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 2024 · Centers for Disease Control and Prevention (CDC), Maximus Federal Services, Inc., ICF

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Access Resources

LectureEN

June 2023 ACIP Meeting - Dengue Vaccines

Access Resources

About

Tags

More like this

Access Resources